ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Economic evaluations of onchocerciasis interventions: a systematic review and research needs.Tropical medicine & international health : TM & IH · 2019Pooled it
- Repurposing Oxfendazole for Onchocerciasis: Population Pharmacokinetics of a Tablet Formulation in Healthy African Adults.CPT: pharmacometrics & systems pharmacology · 2026Trial
- Trial
- Comparison of 6-Week Doxycycline vs 6-Week Rifampicin or 3 Weeks of Doxycycline Plus Rifampicin in the Treatment of Onchocerciasis: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial.Open forum infectious diseases · 2026Article
- Modelling the impact of mass drug administration with ivermectin or moxidectin on human onchocerciasis when there is sub-optimal response of parasites to treatment.Research square · 2026Article
- Onchocerciasis and non-communicable diseases in the Bafut Health District, Cameroon: Knowledge, attitudes, and practices towards community-directed treatment with ivermectin.PLoS neglected tropical diseases · 2026Article
- Neglected Tropical Diseases and Female Infertility: Possible Pathophysiological Mechanisms.Journal of tropical medicine · 2025Review
- Community Perceptions of Blackfly Nuisance and Acceptability of the "Slash and Clear" Vector Control Approach in the Ntui Health District of Cameroon: A Qualitative Study.International journal of environmental research and public health · 2024Article
- Awareness of and participation in mass drug administration programs used for onchocerciasis control in the Atwima Nwabiagya North District, Ghana.Global health research and policy · 2023Article
- A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity.PLoS neglected tropical diseases · 2023Article
- Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness.PLoS neglected tropical diseases · 2023Article
- Financing care for Severe Stigmatizing Skin Diseases (SSSDs) in Liberia: challenges and opportunities.International journal for equity in health · 2022Article
- The prevalence of onchocerciasis in Africa and Yemen, 2000-2018: a geospatial analysis.BMC medicine · 2022Article
- The preparatory phase for ground larviciding implementation for chocerciasis control in the Meme River Basin in South West Cameroon: the COUNTDOWN Consortium alternative strategy implementation trial.Parasites & vectors · 2022Article
- The Human FilariaResearch and reports in tropical medicine · 2022Review
- Ecohydrology 2.0.Rendiconti Lincei. Scienze fisiche e naturali · 2022Review
- Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning.PLoS neglected tropical diseases · 2021Article
- Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 7 countries.
Funding
Abstract
Background: Great strides have been made toward onchocerciasis elimination by mass drug administration (MDA) of ivermectin. Focusing on MDA-eligible areas, we investigated where the elimination goal can be achieved by 2025 by continuation of current practice (annual MDA with ivermectin) and where intensification or additional vector control is required. We did not consider areas hypoendemic for onchocerciasis with loiasis coendemicity where MDA is contraindicated. Methods: We used 2 previously published mathematical models, ONCHOSIM and EPIONCHO, to simulate future trends in microfilarial prevalence for 80 different settings (defined by precontrol endemicity and past MDA frequency and coverage) under different future treatment scenarios (annual, biannual, or quarterly MDA with different treatment coverage through 2025, with or without vector control strategies), assessing for each strategy whether it eventually leads to elimination. Results: Areas with 40%-50% precontrol microfilarial prevalence and ≥10 years of annual MDA may achieve elimination with a further 7 years of annual MDA, if not achieved already, according to both models. For most areas with 70%-80% precontrol prevalence, ONCHOSIM predicts that either annual or biannual MDA is sufficient to achieve elimination by 2025, whereas EPIONCHO predicts that elimination will not be achieved even with complementary vector control. Conclusions: Whether elimination will be reached by 2025 depends on precontrol endemicity, control history, and strategies chosen from now until 2025. Biannual or quarterly MDA will accelerate progress toward elimination but cannot guarantee it by 2025 in high-endemicity areas. Long-term concomitant MDA and vector control for high-endemicity areas might be useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.